Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Delineating the Interplay Between Oncogenic Pathways and Immunity in Anaplastic Wilms Tumors: Implications for Prognosis and Therapeutic Vulnerability

ABSTRACT: Delineating the Interplay Between Oncogenic Pathways and Immunity in Anaplastic Wilms Tumors: Implications for Prognosis and Therapeutic Vulnerability

PROVIDER: PRJNA930435 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23305245_1.fastq.gz	Fastqsanger.gz
	SRR23305245_2.fastq.gz	Fastqsanger.gz
	SRR23305246_1.fastq.gz	Fastqsanger.gz
	SRR23305246_2.fastq.gz	Fastqsanger.gz
	SRR23305247_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Proteasome inhibition sensitizes anaplastic Wilms tumor to actinomycin D

Project description:Wilms tumor is the most common kidney cancer in children, and anaplastic Wilms tumor is the most chemoresistant histological subtype. Here we explore how anaplastic Wilms tumor cells evade the common chemotherapeutic drug actinomycin D, which inhibits ribosomal biogenesis. We found that, when ribosomal capacity is limited by actinomycin D treatment, anaplastic Wilms tumor cells preferentially translate proteasome components and upregulate proteasome activity. Accordingly, increased proteasome levels are associated with anaplastic histology and with worse prognosis in Wilms tumor. Lastly, we show that the proteasome inhibitor bortezomib sensitizes cells to actinomycin D treatment both in vitro and in vivo.

2024-06-20 | GSE270330 | GEO

Delineating the Interplay Between Oncogenic Pathways and Immunity in Anaplastic Wilms Tumors: Implications for Prognosis and Therapeutic Vulnerability

Project description:Through multi-omics profiling, we identified and validated a desert-like DAWT subtype that is closely associated with poor outcomes. This subtype is further characterized by TP53 alterations, cGAS-STING pathway downregulation, low CD8 infiltration, a unique signature of human endogenous retroviruses, and activation of oncogenic pathways involving HDAC and DNA repair.

2023-09-13 | GSE224266 | GEO

Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors.

Project description:Wilms tumors are highly curable in up to 90% of cases with a combination of surgery and radio-chemotherapy, but treatment-resistant types such as diffuse anaplastic Wilms tumors pose significant therapeutic challenges. Our multi-omics profiling unveils a distinct desert-like diffuse anaplastic Wilms tumor subtype marked by immune/stromal cell depletion, TP53 alterations, and cGAS-STING pathway downregulation, accounting for one-third of all diffuse anaplastic cases. This subtype, also characterized by reduced CD8 and CD3 infiltration and active oncogenic pathways involving histone deacetylase and DNA repair, correlates with poor clinical outcomes. These oncogenic pathways are found to be conserved in anaplastic Wilms tumor cell models. We identify histone deacetylase and/or WEE1 inhibitors as potential therapeutic vulnerabilities in these tumors, which might also restore tumor immunogenicity and potentially enhance the effects of immunotherapy. These insights offer a foundation for predicting outcomes and personalizing treatment strategies for aggressive pediatric Wilms tumors, tailored to individual immunological landscapes.

| S-EPMC10689851 | biostudies-literature

Proteasome inhibition sensitizes anaplastic Wilms tumor to actinomycin D

Project description:Proteasome inhibition sensitizes anaplastic Wilms tumor to actinomycin D

| PRJNA1126209 | ENA

Bromodomain 4 inhibition leads to MYCN downregulation in Wilms’ tumor cells

Project description:We have undertaken a functional genomics approach to uncover novel therapeutic strategies efficacious for those patients with anaplastic Wilms’ tumor. Genomic analysis, in vitro chemical screens and microfluidic experiments demonstrate that MYCN over-expression in Wilms’ tumor can be modulated via BRD4 inhibition resulting in a reduction in Wilms’ tumor cell growth.

2020-08-12 | GSE156065 | GEO

Single nuclear RNASeq Analysis of Anaplastic and Favourable Histology Hu_Wilms Tumor

Project description:Wilms tumor is the most common pediatric kidney cancer. The best predictor of clinical outcome for Wilms tumor patients is how their tumor looks under the microscope (histology). Usually, the resistant/anaplastic component of the tumor makes up only a fraction of the total number of cells in the cancer. A critical barrier to understanding therapeutic resistance in this disease is that studies performed to sequence the resistant component is diluted by the other components of the tumor.Therefore, the current proposal aims to using single-nuclear-RNA sequencing to isolate the gene expression patterns of individual cell types in Wilms tumor and to focus on the anaplastic/resistant cells.

2022-04-08 | GSE200256 | GEO

Characterizing MYCN targets in Wilms' tumour

Project description:Transcriptomic analysis of MYCN targets in anaplastic Wilms' tumour cells

| PRJEB41686 | ENA

Transcriptomic Characterization of wilms tumor

Project description:Wilms tumor (WT) is the most common renal malignancy in children. So we aim to investigate the transcriptomic map of Wilms tumor.

2022-05-18 | GSE138869 | GEO

miRNA and Wilms' tumor

Project description:This SuperSeries is composed of the following subset Series: GSE17342: The role of miRNA in Wilms' tumorigenesis GSE28397: Copy number alteration in Wilms' tumor with custom-designed miRNA probes GSE28400: MIR-204 target gene Refer to individual Series

2012-03-30 | E-GEOD-28401 | biostudies-arrayexpress

miRNA and Wilms' tumor

Project description:miRNA and Wilms' tumor

| PRJNA139175 | ENA